The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis.
 
Yinghong Wang
Consulting or Advisory Role - BioNTech; Ilya Pharma; IOTA Pharmaceuticals; Janssen; Kanvas Biosciences; Mallinckrodt; Sorriso Pharmaceuticals
 
Krishnavathana Varatharajalu
No Relationships to Disclose
 
Malek Shatila
No Relationships to Disclose
 
Kristin Junek
No Relationships to Disclose
 
Ninoska Nataly Ninoska
No Relationships to Disclose
 
Pavlos Msaouel
Honoraria - Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Axiom Healthcare Strategies
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Matthew T Campbell
Honoraria - Axdev; Curio Science; Eisai; Exelixis; MJH Life Sciences; Seagen; Targeted Oncology
Consulting or Advisory Role - Exelixis
Research Funding - Apricity Health (Inst); Aravive (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - AVEO; Exelixis; SeaGen
 
Rodabe Navroze Amaria
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Erasca, Inc; Iovance Biotherapeutics; Novartis; Obsidian Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); iovance Biotherapeutics (Inst); KSQ Therapeutics (Inst); Novartis (Inst); Obsidian Therapeutics (Inst); OnKure (Inst)
 
Anusha Thomas
No Relationships to Disclose